Advancements in Understanding the Skin's Microbiomes

Adam Friedman, MD, FAAD, offers highlights from his session at AAD 2023 on how cutaneous dysbiosis plays a role in some common skin conditions.

The impacts of discrimination, harassment, and microaggressions have lasting impact on a clinicians performance, mental health, and career. Heres how to create a respectful culture.

With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.

What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.

Joshua Zeichner, MD, delivered a boot camp on isotretinoin use at AAD 2023, including an overview of newer formulations of the acne drug that could help counter the common absorption challenges.

Patients with common psychocutaneous diseases, including body dysmorphic disorder (BDD), often refuse a psychiatric referral and instead, present to dermatologists and cosmetic surgeons.

A review on breast cancer screenings and procedures on the chest is essential to ensure proper gender-affirming care.

Ronda Farah, MD, FAAD, shares her tips and tricks for treating varying types of alopecia.

The treatment was deemed effective following a phase 3 study.

In a world where she practices dermatology, conducts research, and is a super mom, Alina Bridges, DO has nailed down a strategy to not let emails stress her out.

A key session at the annual meeting will share practical advice and tools to better support you and your patients.

Results from the phase 3 study were presented at an AAD late-breaking research session.

Jack Arbiser, MD, PhD discusses the connection between the skin barrier and anti-aging products.

The use of tanning beds has become a popular practice in society today, however, it remains undisputed that ultraviolet radiation from natural sunlight and indoor tanning machines increases an individuals risk of developing skin cancer.

Sandoz, a Novartis division, expects to launch the new adalimumab biosimilar on July 1, 2023.

By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.

A pair of phase 3 trials met all primary and secondary endpoints after 48 weeks.

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

Draelos shares her top takeaways from the annual AAD meeting in New Orleans.

Results from the phase 3 DERMIS-1 and DERMIS-2 trials were presented at the 2023 American Academy of Dermatology Annual Meeting.

Timber Pharmaceuticals is on its way to developing the first FDA-approved treatment for congenital ichthyosis subtypes.

Prior use of biologics in patients with plaque psoriasis may not impact the efficacy of risankizumab treatment.

Incytes MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

Phase 3 data of Oleogel-S10 was presented in a late-breaking session at AAD 2023 in New Orleans.

Researchers sought to analyze alopecia areata data in populations historically underrepresented in research.

Researchers were unable to determine a definite correlation.

DermaSensors handheld device is awaiting FDA review.

Miller shares upcoming news from the SDPA and important legislative updates for dermatology physician assistants.

In part 3 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.

The selective and reversible Janus kinase inhibitor is being studied in several immune-mediated inflammatory diseases.

Study investigators said this system could have significant clinical implications.

The study also found lasting benefits of the supplement for bone density up to age 4.

More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networkingthere was a lot to pack into AAD 2023! Here are the highlights.

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

Researchers say the treatment is both safe and effective in moderate-to-severe cases.

The UK and Netherlands study assessed tumor response rates among 91 patients.

Originally posted here:

The Weekly Roundup: March 20-24 - Dermatology Times